Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction?

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Mitochondrial dysfunction is a key factor in diseases linked to oxidative stress.
• Changes in mitochondrial DNA (MtDNA) content, measured as the mitochondrial genome to nuclear genome ratio (Mt/N), are observed in various diseases like diabetes, obesity, cancer, and during aging.
• MtDNA content alterations may contribute to oxidative stress, inflammation, and disease pathogenesis.

Purpose of the Study:

• To hypothesize that MtDNA content in body fluids and tissues can serve as a biomarker for mitochondrial dysfunction.
• To review existing evidence supporting the use of MtDNA content as a biomarker.
• To highlight the need for robust methodologies to accurately measure MtDNA content.

Main Methods:

• Review of numerous studies examining MtDNA levels in various body fluids (blood cells, serum, saliva, sperm, cerebrospinal fluid) and tissues.
• Analysis of reported changes in MtDNA content (Mt/N ratio) in relation to different diseases and conditions.
• Identification of methodological limitations in current MtDNA quantification techniques.

Main Results:

• Conflicting data exist regarding MtDNA levels as a disease biomarker.
• Potential reasons for conflicting results include issues with primer specificity, nuclear gene variability, genome size differences leading to dilution bias, and inconsistent template preparation.
• Changes in Mt/N are detectable in circulating cells, suggesting their potential as surrogates for systemic changes.

Conclusions:

• MtDNA content in body fluids is a potential biomarker for mitochondrial dysfunction.
• Current methodologies for measuring Mt/N are flawed and produce unreliable results.
• Development of robust and reproducible methods is crucial for validating MtDNA content as a reliable biomarker.